Skip to main content

RESIHANCE 40MG

RESIHANCE 40MG

DESCRIPTION

resihance 40mg tablet consist of protein kinase inhibitor with a similar structure to sorafenib. It is hoping to act by prohibiting multiple signalling pathways contains in angiogenesis and tumour growth.
resihance 40mg is commonly given after other chemotherapy have been tried without success.
resihance 40mg tablet which is used as prescription drugs under the supervision of medical practioners.

INDICATION

resihance 40mg is an anticancer drug which is;
• Indicated for the treatment of Hepatocellular carcinoma
• Indicated for the treatment of Colorectal cancer
• Indicated for the treatment of Gastrointestinal stromal tumor.


MECHANISM OF ACTION

Regorafenib(resihance 40mg tablet) consist of systemic therapy which works throughout your body to promote fight certain cancers. Regorafenib belongs to a multikinase inhibitor, may work by stopping some proteins on certain normal and cancer cells. In this way, Regorafenib may inhibit cancers from growing and spreading for a period.
Cancer contains the uncontrolled growth of certain cells in the body.
Regorafenib (resihance 40mg)may interfere with the signals which inform cancer cells to replicate and may slow the cancer from spreading to other parts of the body.
Regorafenib may also block the creation of new blood vessels that feed cancer cells.

DOSAGE MANAGEMENT

Hepatocellular carcinoma :
The resihance 40mg tablet usual dose for Hepatocellular carcinoma is 160mg (four 40mg tablets) Po q Day for the first 21 days of each 28-day cycle.
Follow the treatment of this conditions until disease progression or undesirable toxicity
Colorectal cancer :
The usual dose for Colorectal cancer is 160mg (four 40mg tablets) Po q Day for the first 21 days of each 28-day cycle.
Gastrointestinal stromal tumor :
The usual dose for Gastrointestinal stromal tumor is 160mg (four 40mg tablets) Po q Day for the first 21 days of each 28-day cycle.

PRECAUTION

• Have high risk for HFSR/PPES and rash; a more incidence of HFSR resulted in Asian patients; stop and then reduce or stop regorafenib depending on severity and persistence of dermatologic toxicity.
• While on treatment with resihance 40mg will occur Myocardial ischemia and infarction seen in clinical trials; withhold Resihancefor new or acute cardiac ischemia/infarction and restart only after resolution of acute ischemic events.
• When administrating resihance 40mg tablet, one case report of reversible posterior leukoencephalopathy syndrome (RPLS) occurred (1 of 1100 treated patients); discontinue therapy if RPLS occurs.
• Using resihance 40mg treatment will have Serious drug-induced liver injury with fatal outcome appeared in Resihance-treated patients in clinical trials. Some of the cases, liver dysfunction occurred within the first 2 months of treatment and was characterized by a hepatocellular pattern of injury.
• When administrating resihance 40mg tablet will have heavy risk for haemorrhage; stop therapy for severe or life-threatening haemorrhage
• When administrating Resihance 40mg will have high risk of infections resulted; most common infections includes urinary tract
infections, nasopharyngitis, mucocutaneous and systemic fungal infections and pneumonia

DRUG INTERACTION

Co administration of resihance 40mg tablet with strong CYP3A4 inducers will decrease Regorafenib plasma concentrations and increased plasma concentration of active metabolite M-2; M-5.
Co administration of resihance 40mg  with strong CYP3A4 inhibitor will increase Regorafenib plasma concentration and decreased plasma concentration of active metabolite M-2; M-5.
Co administration of Resihance 40mg with BCRP substrate will increased the plasma concentration of the BCRP substrate.

MISSED DOSE

If dose resihance 40mg  is failed to take, Patients must consult with medical practitioner and follow the instructions given by them.
Hence missed dose must be avoid and follow the regular dosing schedule.

PREGNANCY

Pregnancy category D: The drug has no data available on use in pregnant women. Inform pregnant women about the probable hazard to a foetus

CONTACT US

EMAIL ID : millionhealthpharmaceuticals@gmail.com
PHONE NO :
 +91-9940472902


Comments

Popular posts from this blog

Xbira 250mg : Abiraterone acetate Cipla Uses, Side Effect, Price india

Drug profile of Xbira xbira 250mg tablet  are containing an active component known as Abiraterone acetate which exhibits anti-tumor activity against prostate cancer. xbira 250mg  Cipla is a derivative of androstene, which involves in the prohibition process of steroid 17 alpha hydroxylase and containing anti-neoplastic activity. Abiraterone acetate  xbira  is an oral tablet which is an active acetate ester form of steroidal compound known as Abiraterone with anti-androgenic activity. Abiraterone acetate  xbira 250mg tablet  is involved by interfering with testosterone activity by inhibiting the synthesis. PRODUCT DETAILS Brand name: Xbira Active substance: Abiraterone acetate Strength: 250mg Mfg: Cipla Pack: 120 tablets in a container Classified as: Anti-neoplastic agent Prescribing information of Xbira The most important indication of  xbira 250mg tablet   is; Metastatic castration resistance prostate cancer Metastatic high risk c...

sovihep D

sovihep D Description The active substance is Sofosbuvir and Daclatasvir ( sovihep d tablet ), which is an inhibitor of the NS5A protein required for the synthesis of HCV. The main purpose of the  sovihep d  is antiviral therapy. It is active in the fight against viral hepatitis C (genotypes 1, 2, 3, 4). The essence of the impact is to block the development of HCV and its spread in the body of the carrier. HCV exists in different forms known as genotypes. Genotype 1 is the most common type of HCV genotype and  sovihep d tablet  is also the most difficult to treat using other treatments. Mechanism of Action: DCV is an HCV NS5A replication complex inhibitor. This NS5A  sovihep d  viral protein has enzymatic activity that is essential for HCV RNA replication and assembly. In replication it appears to play a role in the formation of a membranous web along with viral protein NS4B, and this web provides a platform for replication. The NS5A protein is compo...

Erlonat 150 mg - Erlotinib Natco tablet Price, Cost India

Drug profile   erlonat    is a Natco pharma item which is containing a functioning substance known as Erlotinib, a first line medication of decision in metastatic phase of non little cell lung tumor. erlonat  150mg  is normally endorsed for the patients who are not counters to less than one chemotherapy regimen. erlonat  150mg tablet  is synthetically described as quinazoline subordinate, with hostile to neoplastic impact against tumor cells. erlonat   is pharmacologically arranged as tyrosine kinase inhibitor. erlonat  150mg    is altogether raising the serum aminotransferase levels amid the treatment and this may causes liver wounds. erlonat  150mg tablet    tablets are containing 150mg of Erlotinib as a hostile to tumor specialist. PRODUCT DETAILS Brand name:  Erlonat    Active constituent: Erlotinib Strength: 150MG Mfg: Natco pharma Pack: 30 tablets per container Catego...